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Abstract LOX-1 is an endothelial receptor for oxidized
low-density lipoprotein (oxLDL), a key molecule in the
pathogenesis of atherosclerosis.The basal expression of
LOX-1 is low but highly induced under the influence of
proinflammatory and prooxidative stimuli in vascular
endothelial cells, smooth muscle cells, macrophages,
platelets and cardiomyocytes. Multiple lines of in vitro
and in vivo studies have provided compelling evidence
that LOX-1 promotes endothelial dysfunction and athero-
genesis induced by oxLDL. The roles of LOX-1 in the
development of atherosclerosis, however, are not simple as
it had been considered. Evidence has been accumulating
that LOX-1 recognizes not only oxLDL but other athero-
genic lipoproteins, platelets, leukocytes and CRP. As
results, LOX-1 not only mediates endothelial dysfunction
but contributes to atherosclerotic plaque formation, throm-
bogenesis, leukocyte infiltration and myocardial infarction,
which determine mortality and morbidity from atheroscle-
rosis. Moreover, our recent epidemiological study has
highlighted the involvement of LOX-1 in human cardio-
vascular diseases. Further understandings of LOX-1 and its
ligands as well as its versatile functions will direct us to
ways to find novel diagnostic and therapeutic approaches to
cardiovascular disease.
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Introduction
The lectin-like oxidized LDL receptor-1 (LOX-1) was
identified as an oxidized LDL (oxLDL) receptor expressed
in vascular endothelium. It is a 50 kDa type II transmem-
brane glycoprotein that structurally belongs to the C-type
lectin family [1]. It contains a short N-terminal cytoplasmic
domain, a single transmembrane domain and an extracellu-
lar domain comprising a neck domain followed by a C-
terminal C-type lectin-like domain. Since the discovery of
LOX-1, we have been enthusiastically pursuing its roles in
cardiovascular diseases including atherosclerosis. LOX-1 is
highly induced in the cardiovascular system by a number of
proinflammatory and prooxidative stimuli and recognizes
various structurally-unrelated molecules or even certain
types of cell as a ligand. It has been now established that
LOX-1 actively contributes to the development of athero-
sclerosis. Furthermore, emerging evidence has been impli-
cating pathological roles of LOX-1 in humans. In this
review, we will describe the roles of LOX-1 in cardiovas-
cular diseases particularly focusing on atherosclerosis, its
versatile functions as a multiligand receptor and the clinical
potential for diagnostic and therapeutic targets.
LOX-1 in cardiovascular systems
Discovery of LOX-1
Atherosclerosis is a chronic, multifactorial inflammatory
disease and a leading cause of coronary heart diseases and
cerebrovascular diseases. Over the decades, there have been
numerous efforts to explain the pathogenesis of atheroscle-
rosis. The response-to-injury hypothesis proposed by Ross
[2, 3] assumes that injury of endothelium (endothelial
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that alter normal vascular homeostasis. The response-to-
retention hypothesis depicts that LDL is delivered to the
subendothelial space, binds to proteoglycans, aggregates
and is taken up by macrophages leading to foam cell
formation [4, 5]. The oxidative modification hypothesis
assumes that LDL must undergo oxidative modification to
be proatherogenic because macrophages avidly take up
oxidatively modified LDL but not native LDL to be foam
cells.
The above hypotheses may not be mutually exclusive
but rather emphasize different concepts as necessary steps
for the initiation of atherosclerosis. OxLDL recruits
circulating monocytes into the intimal space, inhibits them
to leave the intima and generates foam cells but the
proatherogenic properties of oxLDL are not limited to
monocytes/macrophages. In vascular endothelial cells,
oxLDL induces the expression and release of monocyte
chemoattractant protein-1 (MCP-1), inhibits release and/or
function of nitric oxide (NO) and increases the expression
of adhesion molecules such as vascular adhesion molecule-
1 (VCAM-1), which suggests a link between the response-
to-injury and oxidative modification hypothesis. Moreover,
it is known that vascular endothelial cells also internalize
oxLDL through a putative receptor-mediated pathway that
does not involve the macrophage scavenger receptors [6].
In light of these findings, we attempted to identify an
oxLDL receptor from vascular endothelial cells.
Expression cloning strategy was employed to identify an
endothelial oxLDL receptor using a cDNA library of
cultured bovine aortic endothelial cells. After multiple
rounds of transfection-recovery, we successfully identified
a cDNA encoding an endothelial receptor for oxLDL and
designated LOX-1 in 1997 [1]. Chinese hamster ovary cells
expressing LOX-1 (LOX-1-CHO) efficiently bound and
took up [
125I]-labeled oxLDL, which was not observed in
wild type CHO cells. The degradation of [
125I]-labeled
oxLDL was suppressed by unlabeled oxLDL but not native
LDL, indicating that native LDL is not a ligand for LOX-1.
In bovine aortic endothelial cells, an anti-LOX-1 antibody
significantly inhibited [
125I]-labeled oxLDL binding, indi-
cating that LOX-1 is a functional oxLDL receptor in
vascular endothelial cells.
Amino acid sequences of LOX-1
Human LOX-1 is encoded by OLR1 gene located on
chromosome 12p12-p13. LOX-1 consists of four functional
domains, a lectin-like domain located at the C-terminal
region, a connecting neck domain, a transmembrane
domain and an intracellular domain located at the N-
terminal region. The amino acid sequences of LOX-1 are
well conserved among mammals [7].The amino acid
sequences of LOX-1 are, however, distinct from other
known scavenger receptors although they recognize com-
mon ligands such as oxLDL, bacteria and apoptotic cells
[8]. This is likely an example of convergent evolution
where different proteins have been adapted to recognize
common ligands. LOX-1 seems to have evolved in the
context of innate immunity system since the gene clusters
together with a subfamily of C-type lectin receptor (CLEC)
such as dectin-1(CLEC-7A) and CLEC-1 that act as pattern
recognition receptors [9–12]( F i g .1).The amino acid
sequence homology of LOX-1 and other CLEC family
proteins is shown in Table 1.
Cellular responses involving LOX-1
Multiple lines of evidence have demonstrated that activation
of endothelial LOX-1 results in endothelial dysfunction,
characterized by reduced vasodilation, proinflammatory state
and prothrombotic properties. Activation of LOX-1 with
oxLDL induces cell injury and apoptosis in human coronary
artery endothelial cells [13, 14]. It is associated with
increased MCP-1 protein expression and enhanced monocyte
adhesion to endothelial cells through the activation of p42/44
mitogen-activated protein kinase (MAPK) [13]. LOX-1
activation with oxLDL increases the expressions CD40 and
CD40 ligand and subsequent generation of tumor necrosis
factor-α (TNF-α) and P-selectin via protein kinase C (PKC)
activation in human coronary artery endothelial cells [15].
OxLDL binding to LOX-1 also immediately increases
reactive oxygen species (ROS) formation and reduces NO
availability with concomitant activation of NF-κBi nb o v i n e
aortic endothelial cells [16, 17]. In isolated aortas, oxLDL
impairs endothelium-dependent relaxation, which is restored
by the treatment of anti-LOX-1 antibody and in LOX-1 gene
Fig. 1 Genomic organization of
LOX-1 and other CLEC family
genes on human chromosome
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380 Cardiovasc Drugs Ther (2011) 25:379–391deficient (LOX-1 KO) mice [18]. The intercellular signal
transductions following the activation of LOX-1 have been
elusive as the intercellular domain of LOX-1 consists of only
30 amino acids. Recent evidence has shown that a complex
formed by LOX-1 and membrane type 1 matrix metal-
loproteinase (MT1-MMP) has been suggested to underlie the
ROS formation and endothelial nitric oxide synthase (eNOS)
downregulation [19].
LOX-1 is also expressed in vascular smooth muscle
cells, differentiated macrophages and platelets. Low doses
of oxLDL increase proliferation of vascular smooth muscle
cells while high doses of oxLDL induce apoptosis in
vascular smooth muscle cells, both of which could be
inhibited by anti-LOX-1 antibody [20, 21]. LOX-1 is
absent in human monocytes but induced in differentiated
macrophages and substantial amount of oxLDL is taken up
via LOX-1 in macrophages stimulated with lisophosphati-
dylcholine or palmitic acids [22–24].In platelets, LOX-1 is
exposed on the surface in an activation-dependent manner
and LOX-1 inhibition suppresses adenosine diphosphate
(ADP)-induced platelet aggregation [25, 26]. Therefore,
LOX-1 is likely to participate in the development of
atherosclerosis from an early to late stage of the process.
Regulated expression of LOX-1 in disease states
In vitro, the basal expression of LOX-1 is low but it has been
consistently observed that the expression is highly induced by
proinflammatory and prooxidative stimuli in endothelial cells,
smooth muscle cells and macrophages. The stimuli include
TNFα,interleukin-1β (IL-1β),transforming growth factor-β1
(TGF-β1), superoxide anions, hydrogen peroxide, 8-iso-
prostaglandin F2α, and lysophosphatidylcholine [27–35].
The expression is also potentiated by other stimuli such as
glucose,freefattyacids,angiotensinII,endothelin-1andsheer
stress [24, 29, 36–43]. Each of these is actively involved in
the pathogenesis of cardiovascular diseases including athero-
sclerosis. Interestingly, several of the stimuli are also released
in response to LOX-1 activation such as endothelin-1 and
TNF-α and oxLDL itself increases LOX-1 expression,
suggesting that the LOX-1 axis composes a vicious cycle
for the development of atherosclerosis [15, 29, 36, 44].
In line with a number of in vitro results, in vivo LOX-1
expression is also highly upregulated under the influence of
proinflammatory and prooxidative stimuli. Vascular LOX-1
gene expression is markedly enhanced in hypertensive rats
[28, 45–48], hyperlipidemic rabbits [49] and diabetic rats
[50]. Ischemia-reperfusion also increases the LOX-1 ex-
pression in myocardium and kidney [51–54]. Recently, it
has been demonstrated that LOX-1 is highly induced in
adipose tissues in response to high fat diet feeding [55].
Moreover, adipose tissues collected from LOX-1 KO mice
were associated with less expression of inflammatory
cytokines such as MCP-1, macrophage inflammatory
protein-1α and interleukin-6 (IL-6) despite a comparable
level of obesity to wild type mice. As adipose inflammation
in obese states has been suggested to lead to systemic
insulin resistance and atherosclerosis [56], increased LOX-
1 expression in obese adipose tissues may also promote the
development of atherosclerosis.
Conversely, the expression of vascular LOX-1is
inhibited by the several clinical drugs. These include anti-
hypertensive (angiotensin II receptor antagonists, calcium
channel blockers, angiotensin-converting enzyme inhibi-
tors), anti-hyperlipidemic (statins), anti-diabetic (sulfonyl
urea, biguanide, peroxisome proliferator-activated receptor-
γ/PPARγ agonist)and anti-thrombotic (aspirin) agents,
potentially suggesting that the reduced expression of
LOX-1 may partially contribute to the therapeutic outcomes
of those drugs (see also section 5.Clinical significance of
LOX-1 in Cardiovascular Diseases [57–64]). Interestingly,
Chui et al. have reported that treatment of obese diabetic
Over all Lectin-like domain
Identity (%) Similarity (%) Identity (%) Similarity (%)
bovine LOX-1 71 92 80 96
porcine LOX-1 69 92 77 95
rabbit LOX-1 77 95 84 98
rat LOX-1 64 89 67 89
mouse LOX-1 56 87 59 86
dectin-1 35 80 40 84
CLEC-1A 28 68 35 75
CLEC-1B 29 70 28 69
CLEC-9A 29 72 33 73
CLEC-12A 26 63 28 66
CLEC-12B 29 72 35 76
Table 1 Amino acid sequence
homology to human LOX-1 of
homologues and human CLEC
family proteins
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in adipose LOX-1 expression with a concomitant reduction
of serum oxLDL level [65]. The authors speculated that
PPARγ agonists may exhibit anti-atherosclerotic effects
partly by trapping circulating oxLDL in adipocytes.
LOX-1 ligands
Modified lipoproteins
LOX-1 was identified as a receptor for oxLDL that was
prepared by oxidizing LDL chemically with copper sulfate
in vitro. Early studies have demonstrated that LOX-1 also
recognizes other chemically modified lipoproteins such as
acetyl LDL and hypochlorite-modified high-density lip-
oproteins [66–68].
In vitro oxidation of LDL yields lipid peroxides such as
oxidized phosphatidylcholine, acrolein, 4-hydroxynonenal
and malondialdehyde and subsequent modification of apoB
protein [69]. Although such oxLDL is an artificial
molecule, the presence of such materials that chemically
and biochemically resemble the oxLDL has been known in
atherosclerotic lesions in humans and rabbits [70]. Later, a
series of studies using anti-oxLDL specific monoclonal
antibodies have clearly demonstrated the presence of
oxLDL in atherosclerotic lesions and in the circulation of
humans and animals [71–75]. As expected, however,
several of these studies have also illustrated that oxLDL
generated in vivo is heterogeneous with distinctive patterns
of modification on lipid and protein moieties, implicating
the potential that oxLDL with antigenicity to a specific
monoclonal antibody does not necessarily bind to and elicit
biological actions via LOX-1.
In order to demonstrate the presence of oxLDL that
could be a ligand for LOX-1 in vivo, we have developed a
sandwich enzyme-linked immunosorbent assay (ELISA)to
measure LOX-1 ligand containing apoB (LAB) with anti-
apoB antibody and immobilized LOX-1. The plasma level
of LAB was significantly higher in Watanabe heritable
hyperlipidemic rabbits (WHHL) compared to Japanese
white rabbits [76, 77]. Higher concentration of plasma
LAB was also demonstrated in apoE-deficient (apoE KO)
mice, another atherosclerosis-prone animal model [78].
Moreover, aortic root of apoE KO mice accumulated
significant amount of LAB, as evidenced by immunohisto-
chemical staining using extracellular domain of LOX-1 as a
probe [78]. Therefore, oxLDL that could be a ligand for
LOX-1 is highly present in circulation and lesions of
atherosclerosis-prone animals.
Recent evidence has shown that other atherogenic lip-
oproteinssuchascarbamylatedLDL,remnant-likelipoprotein
particle and electronegative LDL mediate proatherogenic
properties by binding to LOX-1 in vitro [79–82]. Therefore,
LAB is likely to include not only oxLDL that could be a
ligand for LOX-1 but other proatherogenic modified LDL,
suggesting that the level of LAB may reflect proatherogenic
states better than measuring the absolute amount of oxLDL
with specific epitope by anti-oxLDL antibody (also see
section 5.3 LOX Index). Interestingly, monocyte adhesion to
human coronary arterial endothelial cells induced by
carbamylated LDL was dependent on LOX-1 whereas the
uptake of carbamylated LDL was equivalently contributed to
by LOX-1 and other scavenger receptors such as scavenger
receptor expressed by endothelial cell-1 (SREC-1), CD36
and scavenger receptor-A (SR-A) [79].
Cellular ligands
LOX-1 recognizes other ligands with no structural similar-
ities to lipoproteins. These include polyanionic chemicals,
anionic phospholipids and cellular ligands [66, 83–87]. The
reported ligands for LOX-1 are summarized in Table 2. The
pathological significance of LOX-1 as a cell adhesion
molecule has been demonstrated as follows.
Activated but not non-activated platelets increase
endothelin-1 release and superoxide production from endothe-
Table 2 LOX-1 ligands as determined by either direct binding assay
or competitive assay (*) against established ligands
LOX-1 ligand Molecule
Lipoproteins oxidized LDL
acetyl LDL
hypochlorite-modified HDL
remnant-like lipoprotein particle
electronegative LDL
carbamylated LDL
Proteins CRP
fibronectin
HSP60, HSP70
Cells activated platelets
leukocytes/monocyte
aged/apoptotic cell
bacteria
Phospholipids phosphatidylserine
phosphatidylinositol*
phosphatidic acid*
cardiolipin*
phosphatidylglycerol*
Polyanions heparin*
dextran sulfate*
poly-inosinic acid*
Others AGE
2-nonenal/4-oxo-nonenal-bound protein
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oxLDL but activated platelets induce endothelial dysfunction
through LOX-1 [44, 84, 86]. Importantly, co-incubation of
activated platelets with endothelial cells almost completely
diminishes endothelial NO release by bradykinin, indicating
that a sufficient amount of superoxide is generated to disrupt
vascular protective effects of NO. Phosphatidylserine (PS)
exposed on activated platelets seems to work as a ligand for
LOX-1 because 1) superoxide generation is significantly
inhibited by annexin V, a PS binding protein, 2) PS liposome,
a ligand for LOX-1 also increases superoxide and 3) platelets
expose PS upon activation.
Incubation of human aortic endothelial cells with high
glucose or C-reactive protein (CRP) increases LOX-1
expression and monocyte adhesion, and the adhesion is
suppressed by anti-LOX-1 antibody [41, 88]. Monocyte
adhesion also initiates ROS generation and NF-κB phos-
phorylation in endothelial cells [89]. In vivo adhesion of
leukocytes to LOX-1 has been demonstrated in endotoxin-
induced inflammation in rats [90]. Flow chamber analysis
demonstrated that leukocytes directly bind to LOX-1. As
adhesion of mononuclear leukocytes to vascular endotheli-
um cells is also considered as an early step in atherogenesis,
LOX-1 may also support leukocyte adhesion during the
development of atherosclerosis.
LOX-1 expressed on vascular endothelial cells binds
to and phagocytoses aged/apoptotic red blood cells [66].
Again, PS on cellular membranes seems to be a key
molecule in the cell recognition by LOX-1 because PS is
exposed on the outer membrane of aged/apoptotic cells
and PS liposome efficiently displaces the binding. Al-
though there is no evidence showing that endothelial
LOX-1 promotes the clearance of aged/apoptotic cells in
vivo, LOX-1 may enhance procoagulant activity by
trapping aged/apoptotic cells on the vascular surface since
apoptotic cells exposing PS are potent procoagulant
molecules [91].
C-reactive protein
CRP is an acute-phase protein released from hepatocytes in
response to inflammation and tissue damage. It binds to
various ligands exposed on damaged tissues or bacteria,
promoting phagocytosis and complement activation [92,
93] and has long been used as an inflammatory biomarker
[94]. Moreover, although still being debated, accumulating
literature reports that CRP induces endothelial dysfunction
[95]. Based on the overlapping biological functions and
clinical implications, we hypothesized that CRP might be a
ligand for LOX-1. Indeed, CRP bound to LOX-1-CHO
cells but not wild type CHO cells [96]. Similar results were
also reported from another group showing that CRP bound
to LOX-1 expressed on bovine aortic endothelial cells [97].
A mutant LOX-1 protein, in which arginine residues at 208,
229, 231 and 248 were displaced with glutamine, still
bound to CRP but not to oxLDL [97, 98], suggesting that
the binding modes of CRP and oxLDL to LOX-1 are
distinctive. The Kd for the binding of CRP to LOX-1 was
1.6×10
−6 M[ 96], which is within the dynamic range of
CRP in response to inflammatory stimuli (> 10
−6 M). CRP
indeed increased the expressions of IL-8, ICAM-1 and
VCAM-1 mRNA through the binding to LOX-1 in trans-
formed human aortic endothelial cells [97].
Although the ligand specificity of the scavenger receptor
family considerably overlaps, we have recently found that
CRP is recognized by LOX-1 and SR-A but not by other
scavenger receptors such as CD36, SR-B1 and CD68 [99].
In vivo, exogenously added CRP enhances the vascular
permeability through binding to LOX-1in rats, implicating
the importance of LOX-1 as a CRP receptor in the
cardiovascular system [96].Recent epidemiological studies
have shown that even a slight increase in the serum
concentration of CRP can be a major risk indicator for
ischemic heart diseases [100–102]. Of particular interest,
the JUPITER (Justification for the Use of Statins in Primary
Prevention: an Intervention Trial Evaluating Rosuvastatin)
study revealed that rosuvastatin significantly reduced the
incidence of major cardiovascular events in people without
hyperlipidemia but with elevated high sensitivity (hsCRP)
[103]. Since statins reportedly reduce the expression of
LOX-1 [104], inhibition of the interplay of CRP and LOX-
1 may underlie the pleiotropic effects of statin.
Other LOX-1 ligands
Heat shock proteins (HSP) were originally described for
their role as chaperones induced by temperature shock as
well as various other kinds of stress and later works have
identified certain types of HRPs including HSP90, HSP70,
HSP60 and HSP27 that were released outside the cell [105].
LOX-1 recognizes HSP60 and HSP70 in dendritic cells,
where it works as a receptor for antigen cross-presentation
[106, 107]. Moreover, targeting a tumor antigen to LOX-1
elicits protective immune responses against antigen-
expressing tumor cells in vivo [106].
Chronic hyperglycemia and increased oxidative stress
generate advanced glycation end products (AGEs), non-
enzymatic reaction products between reducing sugars and
amine residues on protein, lipoproteins and nucleic acids
[108]. The pathological roles of AGEs in diabetic nephrop-
athy have been well elucidated but AGEs also seem to play
multiple roles in the development of atherosclerosis such as
endothelial dysfunction and inhibition of hepatic LDL
clearance. The receptor for AGE (RAGE) is the most
studied receptor for AGEs. Jono et al. have demonstrated
that LOX-1 functions as a receptor for AGEs and a
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bovine aortic endothelial cells is mediated by LOX-1 [109].
VLDL/LDL collected from diabetic rats contains a larger
amount of LOX-1 ligand activity compared to that from
normoglycemic rats and AGE-albumin increases LOX-1
expression in bovine aortic endothelial cells, suggesting
that LOX-1 also plays a role in AGE-mediated endothelial
dysfunction [50].
Uchida’s group has recently identified that lipid perox-
idation products, trans-2-nonenal and 4-oxo-2(E)-nonenal,
covalently bind to protein in vivo and that the modified
proteins induce proinflammatory events via LOX-1 in
human macrophages [110, 111].
Pathological roles of LOX-1; from endothelial
dysfunction to restenosis
Initiation of atherosclerosis
Immunohistochemical studies and gain-of-function and
loss-of-function approaches have provided compelling
evidence that LOX-1 is involved in the development of
atherosclerosis in vivo. LOX-1 is predominantly expressed
in the endothelial cells and to a lesser degree in infiltrated
macrophages of early atherosclerotic lesions in WHHL
rabbits. Importantly, the expression is higher even in non-
lesion areas of the rabbits compared to their wild type
counterpart [112], suggesting that LOX-1 is involved in the
initiation of atherosclerosis. Immunohistochemical studies
also support the involvement of LOX-1 in human. LOX-1
expression is highly expressed on luminal endothelial cells,
especially in the early stage of atherosclerosis and macro-
phages and smooth muscle cells accumulated into the
intima [113]. Evidence is also available showing that LOX-
1 is functionally involved in the initiation of atherosclero-
sis. Mice overexpressing LOX-1 (LOX-1 TG) fed high fat
diet display impaired endothelium-dependent relaxation in
mesenteric arteries at a time when significant atheroscle-
r o t i cl e s i o n sa r ea b s e n t[ 114]. Interestingly, we have
recently found that oxLDL increases vascular permeability
via LOX-1 and thereby enhances lipid retention under
subendothelial space in hypertensive rats [48], which
seems to provide a novel link between the oxidative
modification hypothesis and the response-to-retention
hypothesis.
Genetically-modified mice have also pointed out the
roles of LOX-1in the long-term progression of athero-
sclerosis. LOX-1 TG mice crossed with apoE KO mice
(LOX-1TG/apoE KO) on high fat diet display pro-
nounced lipid accumulation, oxidative stress and in-
creased infiltration of macrophages in the heart and
vessels [115]. In LOX-1 KO mice crossed with LDL
receptor KO mice (LOX-1/LDLR KO), the formation of
atherosclerotic lesions is significantly reduced compared
to LDLR KO mice with a comparable serum LDL level
[18]. Ectopic expression of LOX-1 in the liver of apoE KO
mice ameliorates the development of atherosclerotic
lesions with a reduction in plasma LAB [116]. This study
is particularly important, indicating that 1) proatherogenic
LAB is present in vivo, 2) LAB/LOX-1 axis promotes
atherosclerosis in vivo and 3) eliminating the circulating
LAB is sufficient for preventing atherosclerosis.
Advanced atherosclerosis
The disruption of unstable atherosclerotic plaques and
subsequent formation of occlusive thrombi are currently
considered as the primary cause of acute coronary
syndrome. Apoptotic death of smooth muscle cells in the
fibrous cap of the atherosclerotic plaques in addition to the
degradation of extracellular matrix proteins by matrix
metalloproteinases (MMPs)are considered to be involved
in plaque rupture [117]. Circumstantial evidence support
that LOX-1 regulates atherosclerotic plaque stability.
Thrombosis accompanied in atheroma collected from
patients with unstable angina is clearly stained with anti-
LOX-1 antibody [25]. Saji’s group has reported that LOX-1
expression is intensive in atherosclerotic plaque with
thinner fibromuscular cap and macrophage-rich lipid core
area in WHHL rabbits with advanced atherosclerotic
plaques [49, 118]. In human advanced atherosclerotic
plaques, macrophages and smooth muscle cells in the
intima dominantly express LOX-1, which is co-localized
with Bax, a proapoptoic factor [20, 113].
Role of LOX-1 after the cardiovascular events
Myocardial reperfusion by thrombolysis or primary angio-
plasty has been widely performed for the management of
acute myocardial infarction. Although early reperfusion can
salvage jeopardized myocardium, reperfusion itself causes
myocardial cell injury [119]. Moreover coronary artery
restenosis after angioplasty occurs in ~30% of all patients
[120, 121]. Interestingly, LOX-1 also seems to play a
significant role in a series of events after myocardial
infarction. We observed that the expression of LOX-1 was
significantly increased in medial to intimal smooth muscle
cells after balloon injury of the carotid artery in rats. An
anti-LOX-1 antibody administered after the injury sup-
pressed intimal hyperplasia, oxidative stress and leukocyte
infiltration [122].Similar results were obtained using a gene
silencer targeting LOX-1 [123]. In ischemic myocardium,
the basal expression of LOX-1 is low, however, highly
induced following reperfusion and the administration of
anti-LOX-1 antibody halved myocardial infarction size,
384 Cardiovasc Drugs Ther (2011) 25:379–391adhesion molecule expression and leukocyte recruitment in
rats [51, 52].
Clinical significance of LOX-1 in cardiovascular
diseases
Genetics
Several groups have looked at single nucleotide poly-
morphisms (SNPs) in the human LOX-1 gene to determine
whether they are associated with cardiovascular diseases.
Tatsuguchi et al. have identified an SNP, G501C (K167N), a
missense mutation of LOX-1 protein [124]. Discordant
results have been reported on the association of the SNP
and cardiovascular risk [124–128]. Biochemically, the
binding and uptake of oxLDL were lower in cells
expressing LOX-1 with K167N mutation than native
LOX-1 [129, 130], suggesting that LOX-1 with K167N
mutation may be protective for atherogenesis.
Mango et al. have examined 253 individuals (150
individuals with acute myocardial infarction and 103
healthy controls) and identified 7 SNPs within intron 4, 5,
exon 5 and the 3′-untranslated region (UTR) [125].
Individuals having a C-to-T change in 3′-UTR exhibit a
significant association with acute myocardial infarction
with an odds ratio of 3.74. They have also demonstrated
that the SNP generated a new splicing isoform of LOX-1
that lacks exon 5 (LOXIN) and that LOXIN have a
protective role in LOX-1 mediated apoptosis [131].
Soluble LOX-1 (sLOX-1)
A number of membrane proteins are subjected to proteol-
ysis at the membrane-proximal site of the extracellular
domain. Elevated levels of soluble forms of membrane
proteins in circulating blood have been suggested to reflect
increased expression of the protein and disease states [132–
135]. LOX-1 is also cleaved and released as a soluble form
(sLOX-1) into culture media following treatment with
TNFα and IL-18 and inhibition of ADAM10, a member
of a disintegrin and metalloproteinase (ADAM) family,
suppressed the shedding [136, 137]. Hayashida et al. have
developed a sandwich ELISA to measure sLOX-1 using
two different rabbit antibodies for human LOX-1 and have
demonstrated that serum levels ofsLOX-1are prognostic
biomarkers of early acute coronary syndromes [138–140].
Compared to troponin T and hsCRP, an established
diagnostic biomarker and a predictor for acute coronary
syndrome, respectively, sLOX-1 seems to reflect the
vulnerable atherosclerotic plaque better than the two. They
speculated that LOX-1, highly expressed in macrophages
and smooth muscle found in rupture-prone plaque, was
cleaved under the condition in which protease activity is
elevated.
LOX index as a predictive marker for stroke and coronary
heart disease
We measured LAB of more than 2,000 healthy subjects in a
community-based cohort study [141].During the 11-year
follow-up period, the hazard ratio (HR) of ischemic stroke
was highest in the highest LAB quartile with statistical
significance. In this study, we also measured sLOX-1 by
sandwichELISAusingmousemonoclonalanti-humanLOX-1
antibody and chicken monoclonal anti-human LOX-1
antibody and calculated a parameter “LOX Index”,a
multiplication of LAB and sLOX-1, which we assumed
reflects the biological activity of LOX-1 ligands. The
results demonstrated that LOX Index is a novel predictive
marker for particularly ischemic stroke, and to a lesser
extent coronary heart disease. The multivariable-adjusted
HR for ischemic stroke from second to the top quartile of
LOX Index was constantly 3-fold higher than that of the
bottom quartile after multivariable adjustment. An associ-
ation of LOX-1 with ischemic stroke has been also reported
in experimental animals [142].
It is known that cholesterol is a strong risk factor for
ischemic heart disease but not for ischemic stroke although
atherothrombosis is a common underlying event [143–147].
In accordance to this, in another baseline survey using the
same cohort as our report [141], there was no association
between LDL cholesterol or non-HDL cholesterol concen-
trations and the incidence of ischemic stroke [148]. The
paradox of cholesterol and stroke is also seen in the effect
of statins on stroke incidence; the greater the reduction of
LDL with statin treatment, the lower the risk of stroke
despite the absence of association of baseline LDL and
stroke incidents [149]. In hypercholesteromic patients,
baseline LAB levels did not correlate with LDL cholesterol
and was significantly lowered by pitavastatin [150]. In
WHHL rabbits, LAB as well as the expression of LOX-1
are also reduced by the treatment of statin [60, 77]. Thus,
stroke morbidity and the statins’ benefit might be explained
in the context of LOX-1.
Therapeutic potential of LOX-1 inhibition
for cardiovascular diseases
A number of animal and human studies implicate that
LOX-1 is an attractive therapeutic target for human
cardiovascular diseases. LOX-1 is a unique membrane
receptor in terms that it seems to elicit biological functions
via diverse mechanisms; LOX-1 uptakes oxLDL as an
endocytotic receptor, tethers leukocytes and platelets as an
Cardiovasc Drugs Ther (2011) 25:379–391 385adhesion molecule, and immediately generates ROS
through the activation of intercellular molecules. Moreover,
LOX-1 recognizes diverse ligands with no structural
similarities and importantly, many of the ligands are also
implicated in cardiovascular diseases. To date, we have
developed a mouse monoclonal antibody developed for
LOX-1, which inhibits ligand binding and/or LOX-1
activation with modified lipoproteins, cellular ligands and
proteins in vitro [1, 16, 17, 80, 84–86, 89, 96, 151, 152]. In
vivo, the antibody suppressed arterial lipid accumulation
[48], neointimal hyperplasia in response to arterial injury
[122], CRP-induced vascular hyperpermeability [96], neu-
trophil invasion after lipopolysaccharide challenge in rats
[90] and myocardial ischemia-reperfusion injury [51].
Human monoclonal antibody for human LOX-1 has also
been developed using Xenomouse and it inhibits oxLDL-
induced ROS formation, RhoA/Rac1 activation and MCP-1
expression [19, 89, 153], suggesting that antibody therapy
is feasible. LOX-1 inhibition with small-molecule com-
pounds (drug-like compound) is more useful in terms of
oral availability and medical costs but may be challenging
since LOX-1 seems somewhat different from “druggable”
targets such as G protein-coupled receptors, channels,
enzymes and proteases [154]. However, several small-
molecule inhibitors for SR-A and SR-B1 have been
identified using lipoprotein as a ligand [155, 156].
Moreover, we have recently identified procyanidin, a
polyphenol constituent abundant in red wine and apples
which potently inhibits oxLDL binding to LOX-1 and lipid
accumulation in rats [157], further implicating that the
inhibition of oxLDL to LOX-1 with small molecules might
be feasible. Disruption of CRP-LOX-1 interaction is also an
attractive target, although it would be much more challeng-
ing since inhibition of protein-protein interaction with
small-molecule compounds is considerably difficult [158–
160].Further studies are necessary to investigate the binding
modes of each ligand to LOX-1, and which of the ligand
interactions underlies the specific disease phenotypes.
Concluding remarks
LOX-1 was originally discovered as a receptor for oxLDL
that mediates endothelial dysfunction. The roles of LOX-1
in the initiation and the development of atherosclerosis
have been almost established. The underlying mechanisms
seem far more complex than originally thought as LOX-1
mediates the foam cell formation, proliferation and apopto-
sis of smooth muscle cells, platelet aggregation and cell
adhesion. The recognition of diverse ligands and inducible
expression pattern of LOX-1 in different types of cells are
likely to explain the participation of LOX-1 in multiple
stages of atherosclerosis from endothelial dysfunction to
restenosis. Furthermore, it is intriguing that the major three
hypotheses of atherogenesis could be explained by the
versatile functions of LOX-1 (Fig. 2).
Hyperlipidemia, diabetes and hypertension, referred to as
lifestyle-related diseases, are leading causes for atheroscle-
rosis and subsequent events such as coronary heart disease
and cerebrovascular disease. In addition to these factors,
other factors such as aging, gender and cigarette smoking
further increase the risk of the cardiovascular diseases.
LOX-1 originally may have worked as a host-defense
molecule during the evolution of recognizing bacteria and
other organisms, binding them and excluding them, as in
the case of dectin-1. In the current lifestyle and environ-
ment of developed countries, however, excess amounts of
waste materials are generated by the metabolism of excess
Fig. 2 LOX-1 and the hypothe-
ses of atherogenesis
386 Cardiovasc Drugs Ther (2011) 25:379–391amounts of nutrients, some of which behave like the
organisms which must be excluded. LOX-1 is, then,
activated to exclude such pseudo-organisms, e.g. oxLDL.
This may induce a dysregulated host-defense signal,
resulting in chronic inflammation leading to the promotion
of lifestyle-related disease. We believe that further under-
standing of the versatile functions of LOX-1 would help
establish a novel diagnostic method and therapeutic strategy
for the treatment and/or prevention of cardiovascular
diseases.
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